Effektivnost' i bezopasnost' ingibitorov fosfodiesterazy 5-go tipa u patsientov s erektil'noy disfunktsiey i serdechno-sosudistymi zabolevaniyami
- Authors: Mamedov M.N1, Poddubskaya E.A1, Sharvadze G.G1
-
Affiliations:
- Государственный научно-исследовательский центр профилактической медицины
- Issue: Vol 11, No 5 (2009)
- Pages: 110-113
- Section: Articles
- URL: https://bakhtiniada.ru/2075-1753/article/view/92959
- ID: 92959
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
M. N Mamedov
Государственный научно-исследовательский центр профилактической медицины
E. A Poddubskaya
Государственный научно-исследовательский центр профилактической медицины
G. G Sharvadze
Государственный научно-исследовательский центр профилактической медицины
References
- Верткин А.Л., Пушкарь Д.Ю., Тополянский, Сегал А.С. Эректильная дисфункция. Лечащий врач. 2003; 7: 1–4.
- Borlotti A, Parazzinin F, Collo E, Landoni M. The epidemiology of erectile dysfunction and its risk factors. Int J Androl 1997; 20: 323–8.
- Claes H.I.M., Van Poppel H. The use of sildenafil, tadalafil, and vardenafil in clinical practice. J Sex Med 2004; 1: 42. Abstr O43
- De Busk R, Drory Y, Goldstein I et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol 2000; 86 (2A): 62–8.
- Feldman H.A., Goldstein I, Hatzichristou D.G. et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61.
- Francis S.H., Corbin J.D. Molecular mechanisms and pharmacokinetics of phosphodiesterase - 5 antagonists. Cur Urol Rep 2003; 4: 457–65.
- Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 388: 1397–404.
- Markou S, Perimenis P, Gyftopoulos K et al. Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta - analysis of clinical trial reports. IntJ Impot Res 2004.
- Mc Kinlay J.B. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Importence Res 2000; Suppl. 12: 6–12.
- Montorsi F, Briganti A, Salonia A et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003; 44: 360–5.
- Montorsi F. Assessment, diagnosis, and investigation of erectile dysfunction. Clin Cornerstone 2005; 7: 29–35.
- Muthall J.P. et al. Erectile dysfunction: monitoring response to treatment in clinical practice - recommendations of an international study panel. J Sex Med 2007; 4: 448–64
- Rosen R.C., Riley A, Wagner G et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–30.
- Rosen R.C., Fisher W.A., Eardley I et al. Men's Attitudes to Life Events and Sexuality (MALES) Study. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in he general population. Curr Med Res Opin 2004; 20 (5): 607–17.
- Rotella D.P. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 2002; 1: 674–82.
- Roumeguere T, Wespes E, Carpentier Y et al. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol 2003; 44: 355–9.
- Seftel A.D., Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004; 171 (6, Pt 1): 2341–5.
- Shabsigh R, Perelman M.A., Lockhart D.C. et al. Health issues of men: prevalence and correlates of erectile dysfunction. J Urol 2005; 174: 662–7.
- Shabsigh R, Duval S, Shah M et al. Efficacy of vardenafil for the treatment of erectile dysfunction in men with hypertension: a meta - analysis of clinical trial data. Curr Med Res Opin 2007; 23 (10): 2453-60.
Supplementary files
